Boundless Bio Inc. emerged Sept. 19 with $46.4 million in funding and a claim to new territory: extrachromosomal DNA
Acadia Pharmaceuticals is planning to raise $250 million through a public stock offering.
HEALTH: Consumer Focus on Nutrition Drives Demand
More and more, San Diego-based food companies are placing focus on including functional ingredients in their “better for you” offerings.
DelMar Pharmaceuticals has relocated from British Columbia to San Diego.
San Diego’s SGI-DNA, a spinout of Synthetic Genomics, has raised a $25 million series A round.
MEDICINE: DermTech’s Patch May Change Skin Cancer Diagnostics
Could that suspicious mole be cancerous? DermTech wants doctors to reach for a patch, not a scalpel.
Obalon Therapeutics Inc. announced Dr. Helmuth Billy as medical director for its first company-owned weight-loss treatment center.
BIOTECH: Cancer Drug Developer Plans To Build Its Pipeline
After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market.
Shares of Tocagen fell Sept. 12 after its brain cancer therapy failed a late-stage clinical trial.
The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a share.
GlaxoSmithKline announced it will acquire San Diego’s Sitari Pharmaceuticals – a deal induced by an unusual pact.
MEDICINE: Getting Patients to Appointments or Home Is Goal
An increasingly common destination for Lyft and Uber drivers: San Diego hospitals.
UC San Diego Offering Space to Pharma Industry To Help Develop Drugs
UC San Diego Moores Cancer Center is offering up space on its campus to the pharmaceutical industry in a bid to translate research into medicines for cancer patients.
Mundipharma’s Backing Will Extend Runway, Provide Well-Positioned Support
Clinical trial results have yielded a major payout for Cidara Therapeutics, a San Diego company developing an antifungal drug.
Shares of Acadia Pharmaceuticals rocketed up 63% on Sept. 9 after its drug in a late-stage clinical trial achieved “robust statistical superiority” over a placebo for dementia-related psychosis.